Physician profile

Michael E Pichichero

Pediatrics · Rochester, NY

NPI 1245337047

$168,155.17

in general payments reported to CMS, 2019-2025

10 companies · $53K in 2025

The $53K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$79,725.00
Travel and Lodging$18,477.73
Food and Beverage$316.91

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $95,310.08 2021-2025
Merck Sharp & Dohme LLC $20,613.88 2019-2025
Pfizer INC. $17,433.06 2021-2022
Modernatx, INC. $14,350.38 2021-2022
Sanofi Pasteur INC. $11,559.82 2019-2022
Eli Lilly and Company $5,238.68 2025
Astrazeneca Pharmaceuticals Lp $3,000.00 2023
Photonicare INC $450.00 2022
Henry Schein, INC. $199.27 2020

1 company reported research payments only; those appear in the research section below.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael E Pichichero

$168,155.17

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaxosmithkline, LLC.
Context
The $53K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).

https://glasscript.com/doctor/55779/michael-e-pichichero

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.